These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: in Vitro Evidence. Manetti M; Romano E; Rosa I; Fioretto BS; Guiducci S; Bellando-Randone S; Pigatto E; Cozzi F; Ibba-Manneschi L; Matucci-Cerinic M Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817940 [TBL] [Abstract][Full Text] [Related]
6. Circulating angiopoietin and Tie-2 levels in systemic sclerosis. Dunne JV; Keen KJ; Van Eeden SF Rheumatol Int; 2013 Feb; 33(2):475-84. PubMed ID: 22461185 [TBL] [Abstract][Full Text] [Related]
7. Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension. Kylhammar D; Hesselstrand R; Nielsen S; Scheele C; Rådegran G Scand J Rheumatol; 2018 Jul; 47(4):319-324. PubMed ID: 29528272 [TBL] [Abstract][Full Text] [Related]
8. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Humbert M; Yaici A; de Groote P; Montani D; Sitbon O; Launay D; Gressin V; Guillevin L; Clerson P; Simonneau G; Hachulla E Arthritis Rheum; 2011 Nov; 63(11):3522-30. PubMed ID: 21769843 [TBL] [Abstract][Full Text] [Related]
9. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517 [TBL] [Abstract][Full Text] [Related]
10. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620 [TBL] [Abstract][Full Text] [Related]
11. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort. Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742 [TBL] [Abstract][Full Text] [Related]
12. Serum Tie2 levels: clinical association with microangiopathies in patients with systemic sclerosis. Noda S; Asano Y; Aozasa N; Akamata K; Yamada D; Masui Y; Tamaki Z; Kadono T; Sato S J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1476-9. PubMed ID: 21366713 [TBL] [Abstract][Full Text] [Related]
13. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502 [TBL] [Abstract][Full Text] [Related]
14. Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Simpson CE; Damico RL; Hummers L; Khair RM; Kolb TM; Hassoun PM; Mathai SC Pulm Circ; 2019; 9(3):2045894019859477. PubMed ID: 31384431 [TBL] [Abstract][Full Text] [Related]
15. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Freire M; Vargas-Hitos JA; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Espinosa G; Colunga-Argüelles D; Ortego-Centeno N; Trapiella-Martínez L; Carbonell-Muñoz C; Pla-Salas X; Perales-Fraile I; Corbella X; Fonollosa-Pla V; Simeón-Aznar CP; J Rheumatol; 2020 Jan; 47(1):89-98. PubMed ID: 30770503 [TBL] [Abstract][Full Text] [Related]
16. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. Reiseter S; Molberg Ø; Gunnarsson R; Lund MB; Aalokken TM; Aukrust P; Ueland T; Garen T; Brunborg C; Michelsen A; Abraityte A; Hoffmann-Vold AM Arthritis Res Ther; 2015 Aug; 17(1):231. PubMed ID: 26315510 [TBL] [Abstract][Full Text] [Related]
17. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Colunga-Argüelles D; Argibay A; Marí-Alfonso B; Marín-Ballvé A; Pla-Salas X; Chamorro AJ; Castro-Salomó A; Madroñero-Vuelta AB; Sánchez-García ME; Sáez-Comet L; González-Echávarri C; Ortego-Centeno N; Vargas-Hitos JA; Todolí-Parra JA; Trapiella-Martínez L; Lledó GM; Freire M; Fonollosa-Pla V; Simeón-Aznar CP; Rheumatology (Oxford); 2021 Feb; 60(2):872-880. PubMed ID: 32844220 [TBL] [Abstract][Full Text] [Related]
18. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685 [TBL] [Abstract][Full Text] [Related]
20. Imbalanced serum levels of Ang1, Ang2 and VEGF in systemic sclerosis: Integrated effects on microvascular reactivity. Michalska-Jakubus M; Cutolo M; Smith V; Krasowska D Microvasc Res; 2019 Sep; 125():103881. PubMed ID: 31075243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]